151273-41-5

Basic information

• Product Name: tert-butyl 4-(5-nitro-1H-indol-3-yl)-5,6-dihydropyridine-1(2H)-carboxylate
• Synonyms: tert-butyl 4-(5-nitro-1H-indol-3-yl)-5,6-dihydropyridine-1(2H)-carboxylate;4-(5-Nitro-1H-indol-3-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester
• CAS NO: 151273-41-5
• Molecular Formula: C₁₈H₂₁N₃O₄
• Molecular Weight: 343.37704
• EINECS: -0
• Mol File: 151273-41-5.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• CAS DataBase Reference: tert-butyl 4-(5-nitro-1H-indol-3-yl)-5,6-dihydropyridine-1(2H)-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 4-(5-nitro-1H-indol-3-yl)-5,6-dihydropyridine-1(2H)-carboxylate(151273-41-5)
• EPA Substance Registry System: tert-butyl 4-(5-nitro-1H-indol-3-yl)-5,6-dihydropyridine-1(2H)-carboxylate(151273-41-5)

Safety Data

• Hazardous Substances Data: 151273-41-5(Hazardous Substances Data)

Upstream product

• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 6146-52-7 5-nitroindole 
• 124-41-4 sodium methylate 
• 914349-31-8 tert-butyl 3-bromo-5-nitro-1H-indole-1-carboxylate 
• 375853-82-0 tert-Butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-1(2H)-pyridinecarboxylate 

Relevant articles and documents

RORC2 INHIBITORS AND METHODS OF USE THEREOF

The present invention provides compounds, pharmaceutical compositions, methods of inhibiting RORγ activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such compounds and pharmaceutical compositions.

INDOLE COMPOUNDS AND METHODS FOR TREATING VISCERAL PAIN

The invention features methods of treating visceral pain or a condition in a mammal caused by the action of nitric oxide synthase (NOS) or by the action of serotonin 5HT1D/1B receptors, by administering to a patient in need thereof a therapeutically effec

Substituted indole compounds having NOS inhibitory activity

The present invention features inhibitors of nitric oxide synthase (NOS), particularly those that selectively inhibit neuronal nitric oxide synthase (nNOS) in preference to other NOS isoforms. The NOS inhibitors of the invention, alone or in combination w